Frequently Asked Questions

Perimenopause is the transition leading up to menopause, when hormone levels fluctuate and symptoms often begin. You are still having periods, even if they're irregular. Menopause is a single point in time: the day you've gone 12 consecutive months without a period (average age around 51 to 52). Everything after that day is postmenopause. Most of the years women spend "in menopause" are actually perimenopause and postmenopause.

It varies widely, but it commonly lasts four to eight years. Some women notice changes for only a year or two; others experience symptoms for a decade. The unpredictability is one of the most frustrating parts, which is why tracking your symptoms is so useful.

Yes, and this is one of the most under-recognized facts. You can have regular or irregular periods and still be deep in perimenopause with significant symptoms. Hormonal shifts begin long before periods stop.

Probably not. Perimenopause commonly begins in the early-to-mid 40s, and for some women in their late 30s. Symptoms appearing at this age are frequently dismissed or misattributed. Recognizing them early is empowering, not alarming. (Menopause before 40 is called premature menopause or primary ovarian insufficiency and deserves specific medical attention, see the section on special situations.)

Because hormone levels (especially FSH) swing dramatically day to day during perimenopause, a single blood test is unreliable and can be normal even when you're clearly symptomatic. For most women over 45, diagnosis is based on symptoms and cycle changes, not bloodwork. Testing is mainly useful when menopause is suspected before age 40 to 45.

Far more than hot flashes. Beyond hot flashes and night sweats, common symptoms include sleep disruption, anxiety, low mood, irritability or "rage," brain fog and memory lapses, joint and muscle aches, heart palpitations, headaches, vaginal dryness, urinary changes and recurrent UTIs, reduced libido, skin and hair changes, and shifts in where the body stores fat.

It's very real and well-documented: difficulty with word-finding, concentration, and short-term memory. The reassuring part is that for most women it is temporary, tied to the hormonal turbulence of the transition, and tends to improve in postmenopause. It is not early dementia, though it understandably can feel that way.

Hormonal changes directly influence mood-regulating brain chemistry, and many women experience new or worsened anxiety, irritability, low mood, or a short fuse during perimenopause, often before they connect it to hormones. Disrupted sleep amplifies all of it. This is a recognized part of the transition and is treatable, not a personal failing.

They can be. Estrogen affects joints, connective tissue, and the cardiovascular system, so new aches, stiffness, palpitations, and even frozen shoulder are reported during this time. Palpitations and any chest symptoms should always be checked by a clinician to rule out other causes, but menopause is a genuine and often-overlooked contributor.

Most symptoms ease in the years after menopause, though hot flashes can persist for several years and, for some women, longer. Genitourinary symptoms (vaginal and urinary) are the exception: they tend to be chronic and progressive without treatment, because they're driven by ongoing low estrogen in those tissues.

This is the single biggest source of fear, and it's based on early interpretations of the 2002 Women's Health Initiative study, which involved older women, higher doses, and older formulations than are typically used today. Current consensus from The Menopause Society is that for most healthy women under 60 or within 10 years of menopause, the benefits of hormone therapy outweigh the risks. In 2025, the FDA removed the long-standing boxed warnings on menopausal hormone therapy after reevaluating that older data.

It's smaller and more nuanced than the headlines suggest. Estrogen-only therapy (for women without a uterus) has not been shown to increase breast cancer risk and may even slightly lower it. Combined estrogen-progestogen therapy is not associated with a meaningful increase in the first several years of use; a small increase may appear with longer-term use. For perspective, this added risk is comparable to or smaller than lifestyle factors like regular alcohol intake. Personal and family history matter, so this should be discussed individually.

Yes. The evidence favors starting within about 10 years of menopause or before age 60, when the benefit-to-risk balance is most favorable (the "timing hypothesis"). Starting many years after menopause changes that balance, particularly for cardiovascular considerations.

There is no mandatory stop date or arbitrary age cutoff. Guidance has moved away from "lowest dose for shortest time" toward individualized, periodic review of your benefits and risks with your clinician. Many women continue safely for years; the decision is revisited over time, not forced.

Body-identical (or bioidentical) hormones are FDA-approved forms, such as estradiol and micronized progesterone, that are molecularly identical to the hormones your body once produced. These are regulated and well-studied. This is different from custom-compounded "bioidentical" hormones and pellets, which are unregulated, not FDA-approved, and discouraged by The Menopause Society due to safety and consistency concerns.

The route of delivery affects the risk profile. Estrogen delivered through the skin (patch, gel, or spray) bypasses the liver and is generally associated with a lower risk of blood clots than oral estrogen, which is why it is often preferred, especially for women with certain risk factors. Your clinician can match the form to your health profile.

Estrogen alone can thicken and overstimulate the uterine lining, raising the risk of uterine cancer. Adding progesterone (often micronized progesterone) protects the lining. Women without a uterus typically don't need it.

This is a common worry, but hormone therapy is not shown to cause weight gain. Menopause itself is associated with a shift toward storing more fat around the abdomen, regardless of HRT, and some evidence suggests hormone therapy may actually help with that redistribution. Weight management in midlife is driven more by muscle loss, sleep, and lifestyle than by HRT.

Yes. It's the most effective treatment for hot flashes and night sweats and for genitourinary symptoms, and it's proven to prevent bone loss and fractures. Many women also report improvements in sleep, mood, joint comfort, and skin. It is not a cure-all, and benefits vary by individual.

HRT isn't suitable for everyone. It's generally not recommended for women with a current or past history of breast cancer or certain hormone-sensitive cancers, unexplained vaginal bleeding, active liver disease, or a history of certain blood clots or stroke, among others. This is exactly the kind of decision that requires a clinician who knows your full history.

There are effective non-hormonal paths. These include two newer prescription medications developed specifically for hot flashes, certain antidepressants (SSRIs/SNRIs) at low doses, gabapentin, cognitive behavioral therapy (CBT), and evidence-based lifestyle strategies. Vaginal symptoms can be treated locally without systemic hormones.

Evidence for most over-the-counter supplements (such as black cohosh or soy isoflavones) is mixed and generally weak, and "natural" does not guarantee safe: some interact with medications. We encourage caution and a conversation with a clinician before spending on unproven products, especially compounded hormone pellets marketed as natural.

These are part of the genitourinary syndrome of menopause (GSM), caused by declining estrogen in vaginal and urinary tissues. Unlike hot flashes, GSM tends to be chronic and to worsen over time without treatment. But it responds very well to treatment, so it does not have to be permanent.

Low-dose vaginal estrogen works locally with minimal absorption into the bloodstream, and carries minimal to no increased risk of breast or uterine cancer. It is considered safe for most women and can dramatically improve comfort, sex, and urinary symptoms. Even many breast cancer survivors may use it when non-hormonal options have not worked, a decision made together with their oncologist.

Recurrent urinary tract infections and urinary urgency are part of GSM: the same estrogen decline that affects vaginal tissue also affects the urinary tract. Treating the underlying tissue changes (often with local vaginal estrogen) can reduce recurrent UTIs, not just the discomfort.

Low libido in midlife has many contributors: hormones, sleep, mood, relationship factors, and comfort during sex. Treating GSM and sleep often helps significantly. For some women with distressing low desire that has not responded to other measures, testosterone therapy may be considered (often off-label, under specialist guidance).

Estrogen protects bone, so its decline accelerates bone loss and raises the risk of osteoporosis and fractures. Hormone therapy is proven to prevent this loss, and weight-bearing and strength exercise, adequate calcium and vitamin D, and not smoking all help. Bone density screening becomes important in this stage of life.

Cardiovascular risk rises after menopause as estrogen's protective effect fades. This makes midlife a critical window for attention to blood pressure, cholesterol, blood sugar, activity, and weight. When started near menopause, hormone therapy is not harmful to the heart and may be favorable; starting it much later is a different conversation.

Menopausal brain fog is not the same as dementia and usually improves. While long-term brain health deserves attention through exercise, sleep, cardiovascular health, and mental engagement, the short-term cognitive symptoms of the transition are not a reliable predictor of future dementia.

Yes, and it matters. Early or premature menopause (including primary ovarian insufficiency) carries higher long-term risks to bone, heart, and brain health because of the longer time without estrogen. Unless there's a specific contraindication, hormone therapy is generally recommended at least until the average age of natural menopause (around 52). This is replacement of what the body would normally have, not optional treatment.

Surgery that removes the ovaries causes an abrupt, often intense menopause rather than a gradual transition. Symptoms can be sudden and severe, and the same long-term health considerations as early menopause apply. Hormone therapy is frequently recommended unless contraindicated; discuss timing and options with your clinician.

Not entirely. Systemic hormone therapy is generally avoided after breast cancer, but you still have effective non-hormonal options for hot flashes, and low-dose vaginal estrogen may be considered for severe genitourinary symptoms when non-hormonal measures fail, always in partnership with your oncologist. You deserve symptom relief; the path is just more tailored.

Yes. You can still ovulate and conceive during perimenopause, even with irregular periods. Contraception is generally advised until you've had 12 months without a period (or per your clinician's guidance based on age). Some contraceptive methods can also help manage perimenopausal symptoms.

The most evidence-backed steps are regular exercise (especially strength training to preserve muscle and bone), prioritizing sleep, limiting alcohol and caffeine if they trigger symptoms, not smoking, managing stress, and a balanced diet with adequate protein, calcium, and vitamin D. These won't replace medical treatment for significant symptoms, but they meaningfully improve how you feel and protect long-term health.

Consider expert support if symptoms are disrupting your work, sleep, relationships, or quality of life; if you're unsure whether HRT is right for you; if you had early or surgical menopause; if you have a complex health history; or if you simply want clear, personalized answers. That's precisely what ResetWell Plus is here for: connecting you with knowledgeable, up-to-date menopause care.